XOMA Announces March 8 Conference Call and Webcast Discussion of Fourth Quarter and Full-Year 2006 Results
Friday March 2, 2:00 pm ET
BERKELEY, Calif., March 2, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (NasdaqGM:XOMA - News) will issue a news release announcing its fourth quarter and full-year 2006 financial results for the periods ended December 31, 2006, on Thursday, March 8, 2007, at 4:00 p.m. Eastern (1:00 p.m. Pacific). The news release will be followed by a conference call and live webcast at 5:00 p.m. Eastern (2:00 p.m. Pacific) with XOMA management discussing fourth quarter and full-year financial results and providing a general business update. There will be a question and answer session at the end of the conference call.
The webcast can be accessed via XOMA's website at xoma.com and will be archived on the site and available for replay until close of business on June 8, 2007. To obtain phone access to the live audiocast in the U.S. and Canada, dial 1-877-407-9205. International callers should dial 1-201-689-8054. No conference ID is necessary. An audio replay will be available by telephone beginning two hours following the conclusion of the webcast through 11:59 p.m. Eastern (8:59 p.m. Pacific) on March 22, 2007. Access numbers for the replay are 1-877-660-6853 (U.S./Canada) or 1-201-612-7415 (International). Two access numbers are required for the replay: account number 286 and conference ID number 232186.
ADVERTISEMENT
About XOMA
XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono S.A.) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(r) (ranibizumab injection), a monoclonal antibody product marketed worldwide (by Genentech and Novartis AG) to treat neovascular (wet) age-related macular degeneration.
The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering(tm) and bacterial cell expression (BCE) technologies. More than 45 companies have signed BCE licenses. XOMA's development collaborators include Lexicon Pharmaceuticals, Inc., Novartis, Schering-Plough Corporation (NYSE:SGP - News) and Takeda Pharmaceutical Company Limited. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch. For more information, please visit the company's website at xoma.com. |
